Doctor-Supervised Semaglutide & Tirzepatide Programs
Last updated [May, 2026]
Lose weight under licensed medical supervision — without crash diets or guesswork.
Limitless Alternative Medicine offers online, physician-guided medical weight loss using GLP-1 receptor agonist therapy. Eligible patients receive a personalized treatment plan with semaglutide or tirzepatide, shipped discreetly to their door, with ongoing provider oversight throughout the program.
100% online · Licensed providers · HIPAA-compliant intake
Why Diets Fail – and What Actually Changes With GLP-1 Therapy
Most people don’t fail diets. Their biology pushes back.
When you lose weight through caloric restriction alone, your body adapts. Hunger hormones like ghrelin climb. Satiety hormones drop. Resting metabolic rate slows by more than would be predicted from the weight loss itself – a phenomenon documented in the long-term follow-up of The Biggest Loser participants and replicated in multiple controlled studies. This is metabolic adaptation, and it’s why roughly 80% of people who lose significant weight regain it within a few years.
GLP-1 receptor agonists work on a different lever entirely.
Glucagon-like peptide-1 is a hormone your gut produces after meals. It signals fullness to your brain, slows gastric emptying, and helps regulate insulin response. Semaglutide and tirzepatide are synthetic peptides that activate these same receptors — tirzepatide also activates GIP receptors – but at a much more sustained level than your body produces on its own.
Hunger between meals becomes quieter. Portions shrink without willpower. Food noise – the constant background chatter about what to eat next – fades.
What the clinical evidence shows:
In the STEP-1 trial, adults with overweight or obesity taking semaglutide 2.4 mg weekly lost an average of 14.9% of body weight over 68 weeks, compared with 2.4% on placebo (Wilding et al., NEJM, 2021). In the SURMOUNT-1 trial, participants on tirzepatide 15 mg lost an average of 20.9% of body weight over 72 weeks (Jastreboff et al., NEJM, 2022).
Individual results vary substantially.
Semaglutide vs. Tirzepatide: How They Differ
Both medications are weekly subcutaneous injections. Both work on the GLP-1 pathway. They are not interchangeable, and the right choice depends on your medical history, prior medication response, tolerability, and provider judgment.
Semaglutide
Semaglutide is a single-receptor GLP-1 agonist. It’s the active ingredient in Wegovy (FDA-approved for chronic weight management) and Ozempic (FDA-approved for type 2 diabetes). It has the longer real-world track record of the two, with safety and efficacy data extending back more than a decade in diabetes populations.
Typical considerations: Slower titration schedule, generally well-tolerated GI profile compared to older GLP-1s, longer outcomes data in cardiovascular populations.
Tirzepatide
Tirzepatide is a dual GIP/GLP-1 receptor agonist. It’s the active ingredient in Zepbound (FDA-approved for chronic weight management) and Mounjaro (FDA-approved for type 2 diabetes). The added GIP activity appears to produce greater average weight loss in head-to-head and indirect comparisons, though with a similar GI side effect profile.
Typical considerations: Higher average weight loss in trial populations, may be appropriate when semaglutide response has plateaued or for patients with significant insulin resistance.
Important: Medication selection, dosing, and titration are clinical decisions made by your provider based on your individual health profile. Do not self-select or self-titrate.
How the Program Works
Step 01
Confidential Medical Intake
Complete a secure, HIPAA-compliant health questionnaire covering medical history, current medications, prior weight loss attempts, lab work (if available), and treatment goals. Expect to spend 10–15 minutes.
Step 02
Provider Review & Eligibility Determination
A licensed medical provider reviews your submission and determines whether GLP-1 therapy is clinically appropriate. If additional information or lab work is needed, you’ll be contacted before any prescription is issued. Some patients are not candidates — and we will tell you if that’s the case.
Step 03
Personalized Prescription & Discreet Delivery
If approved, your provider issues a prescription with an individualized titration schedule. Medication ships discreetly to your address with detailed administration instructions, a sharps container, and educational materials.
Step 04
Ongoing Clinical Oversight
Your provider monitors response, tolerability, and side effects. Dose adjustments, breaks, or discontinuation decisions are made based on your progress — not a one-size-fits-all schedule. You can message the clinical team between check-ins.
Who Is a Candidate – and Who Isn’t
GLP-1 therapy is intended for adults who meet clinical criteria for medical weight management. Eligibility is determined by a licensed provider, but general guidelines typically include:
- Adults with a BMI of 30 or higher (obesity), or
- Adults with a BMI of 27 or higher (overweight) and at least one weight-related condition such as type 2 diabetes, hypertension, dyslipidemia, or obstructive sleep apnea
You should not use GLP-1 therapy if you:
- Have a personal or family history of medullary thyroid carcinoma (MTC)
- Have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Are pregnant, trying to become pregnant, or breastfeeding
- Have a history of pancreatitis
- Have severe gastroparesis or other significant GI motility disorders
- Have a known hypersensitivity to semaglutide, tirzepatide, or any inactive ingredients
- Are under 18 years of age
Be candid in your intake. Withholding medical history puts your safety at risk and may result in prescriptions being declined or revoked.
Side Effects, Risks, and Warnings
GLP-1 medications are clinically effective, but they are not without risk. We believe patients deserve a full picture before starting therapy — not after.
Boxed Warning
Semaglutide and tirzepatide carry an FDA boxed warning regarding the risk of thyroid C-cell tumors observed in rodent studies. It is unknown whether this risk applies to humans. These medications are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN 2.
Common Side Effects
The most frequently reported side effects are gastrointestinal and tend to occur during dose escalation:
- Nausea (most common)
- Constipation or diarrhea
- Vomiting
- Abdominal pain or bloating
- Fatigue, especially early in treatment
- Injection site reactions
Most GI effects diminish as your body adjusts. Slow, individualized titration is one of the primary ways we reduce side effect burden.
Serious Risks (Less Common)
- Acute pancreatitis
- Gallbladder disease (cholelithiasis, cholecystitis)
- Acute kidney injury, typically secondary to dehydration from prolonged GI symptoms
- Hypoglycemia, particularly when combined with insulin or sulfonylureas
- Worsening diabetic retinopathy in patients with pre-existing disease
- Loss of lean muscle mass, particularly without adequate protein intake and resistance training
Call your provider immediately if you experience severe abdominal pain that radiates to the back, persistent vomiting, signs of an allergic reaction, or symptoms of low blood sugar.
What to Expect: Realistic Timeline
Weeks 1 – 4
Starting dose. Most patients notice reduced appetite within the first one to two weeks. GI side effects, if they occur, are usually most prominent in this window.
Weeks 4 – 12
Dose escalation per your provider’s schedule. Weight loss typically becomes more visible. Energy patterns and food preferences often shift.
Months 3 – 6
Maintenance dosing for most patients. Weight loss continues at a slower, more sustainable pace. This is the phase where building strength training and protein intake habits matters most for preserving lean mass.
Months 6 – 12+
Long-term planning. Many patients approach or exceed their initial goals. Some plateau and require dose review or medication switch. Long-term strategy — continued therapy, tapered dose, or discontinuation with lifestyle support — is a discussion with your provider.
Clinical trial data show that most patients who discontinue GLP-1 therapy without ongoing lifestyle support regain a significant portion of lost weight within a year. Obesity is a chronic condition, and treatment planning should reflect that.
Lifestyle Support That Multiplies Results
GLP-1 therapy reduces appetite. It does not choose what you eat, lift weights for you, or hydrate you.
The patients who get the best, most durable outcomes treat the medication as one tool inside a broader plan.
Protein intake. A common target is roughly 0.7–1.0 g of protein per pound of goal body weight per day. Reduced appetite makes it easy to under-eat protein, which accelerates lean mass loss.
Resistance training. Two to four sessions per week of strength work meaningfully shifts the ratio of fat lost to muscle preserved. Cardio is a supplement, not a substitute.
Hydration and electrolytes. Reduced food intake means reduced water and sodium from food. Mild dehydration amplifies fatigue, constipation, and headaches — side effects often misattributed to the medication itself.
Sleep. Inadequate sleep blunts weight loss and increases cravings independent of medication.
Why Patients Choose Limitless Alternative Medicine
Licensed providers, not algorithms. Every prescription is reviewed and issued by a credentialed medical provider.
Individualized titration. Your dose schedule reflects your tolerability, not a fixed template.
Transparent expectations. We discuss side effects, plateaus, and maintenance up front — not after you’ve started.
Ongoing access. Message your clinical team between check-ins. Don’t wait until a problem becomes a crisis.
Private and discreet. Fully online intake. HIPAA-compliant. Plain packaging.
No upsells on unproven products. No fat burners, no proprietary supplements, no “metabolic resets.”
Start Your Medical Evaluation
You don’t need more motivation. You need the right medical support.
Complete your online intake in about 10 minutes. A licensed provider will review your information and respond with a clinical decision.
Frequently Asked Questions
Is this the same as Ozempic, Wegovy, Mounjaro, or Zepbound?
Semaglutide is the active ingredient in Ozempic (FDA-approved for type 2 diabetes) and Wegovy (FDA-approved for chronic weight management). Tirzepatide is the active ingredient in Mounjaro and Zepbound. Your provider will determine which medication is clinically appropriate based on your history and goals. Brand-name versus compounded sourcing will be disclosed before any prescription is issued.
Do I need to see a doctor in person?
No. The entire intake, provider review, and ongoing follow-up process is completed online. Some patients may be asked to provide recent lab work or, in rare cases, to follow up with an in-person provider depending on their clinical situation.
How much weight will I lose, and how fast?
Results vary substantially by individual. In the STEP-1 trial, the average weight loss on semaglutide 2.4 mg was 14.9% of body weight over 68 weeks. In SURMOUNT-1, the average on tirzepatide 15 mg was 20.9% over 72 weeks. These are averages, not promises. Some patients lose more, some less, and some do not respond to GLP-1 therapy at all. Sustainable weight loss is gradual, not immediate.
Is this covered by insurance?
Coverage varies widely by insurer, plan, diagnosis, and medication. Many cash-pay medical weight loss programs, including ours, operate outside of insurance. Our team can help clarify pricing and payment options during your intake.
What happens when I stop taking the medication?
Clinical evidence indicates that most patients who discontinue GLP-1 therapy without ongoing lifestyle support regain a significant portion of lost weight within a year. This is consistent with how chronic conditions generally behave when treatment is stopped. Long-term planning — including possible maintenance dosing, tapered discontinuation, or transition to lifestyle-only management — is a conversation to have with your provider before stopping.
Can I drink alcohol on semaglutide or tirzepatide?
There is no formal contraindication, but many patients find their tolerance for alcohol drops significantly, and alcohol can worsen GI side effects, dehydration, and hypoglycemia risk. Discuss your specific situation with your provider.
What if I have side effects?
Mild GI side effects are common, particularly during dose escalation, and typically diminish over time. Severe abdominal pain, persistent vomiting, signs of an allergic reaction, or symptoms of dehydration warrant immediate contact with your provider or, in an emergency, with local emergency services. Dose reduction, slower titration, or medication change are all options your provider can offer.
References
Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002.
Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216.
U.S. Food and Drug Administration. Prescribing information for Wegovy (semaglutide) injection.
U.S. Food and Drug Administration. Prescribing information for Zepbound (tirzepatide) injection.
This page is for informational purposes and is not a substitute for individualized medical advice. Read it alongside, not in place of, a conversation with a licensed provider. Limitless Alternative Medicine provides medical services in accordance with applicable federal and state laws and clinical standards. Eligibility, medication, and dosing decisions are made by licensed providers based on individual evaluation. Results vary. Semaglutide and tirzepatide carry an FDA boxed warning regarding the risk of thyroid C-cell tumors and are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN 2.
